M. Cheng

发表

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.

B. Ruggeri, T. Underiner, B. Dorsey, 2006, Blood.

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes

O. Elemento, G. Inghirami, I. Kwee, 2016, Oncotarget.

Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.

G. Tonini, A. Anichini, M. Di Nicola, 2009, Cancer research.

Development of Anti-CD74 Antibody-Drug Conjugates to Target Glucocorticoids to Immune Cells.

D. Zaller, S. Antonenko, A. Palmieri, 2018, Bioconjugate chemistry.

Abstract 3853: Humanized NOD/Scid/IL2g-/- tumor grafts recapitulate primary anaplastic large cell lymphoma.

S. Pileri, R. Rabadán, B. Falini, 2013 .

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).

A. Ghose, P. Dobrzanski, E. Bruckheimer, 2016, Journal of medicinal chemistry.

Malignant Transformation of CD4+ T Lymphocytes Mediated by Oncogenic Kinase NPM/ALK Recapitulates IL-2–Induced Cell Signaling and Gene Expression Reprogramming

J. Tobias, S. Turner, M. Wasik, 2013, The Journal of Immunology.

ReprogrammingSignaling and Gene Expression Induced Cell - NPM/ALK Recapitulates IL-2 Lymphocytes Mediated by Oncogenic Kinase T + Malignant Transformation of CD4

J. Tobias, S. Turner, M. Wasik, 2013 .

Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy.

Theodore A. Martinot, J. O'neil, J. Cumming, 2020, ACS medicinal chemistry letters.

Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1).

Patrick J. Curran, Mee Ra Heo, M. Augustin, 2020, ACS medicinal chemistry letters.

Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.

A. Ghose, B. Ruggeri, K. Wells-Knecht, 2012, Journal of medicinal chemistry.

Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.

A. Ghose, B. Dorsey, T. Angeles, 2011, Bioorganic & medicinal chemistry letters.

Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.1³,⁷.1⁹,¹³]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles.

A. Ghose, K. Wells-Knecht, H. Breslin, 2012, Journal of medicinal chemistry.

Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase

A. Ghose, B. Dorsey, T. Angeles, 2012 .

Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy.

Theodore A. Martinot, Michael J. Ardolino, Xiao Wang, 2019, ACS medicinal chemistry letters.

2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.

A. Ghose, B. Ruggeri, D. Gingrich, 2011, Journal of medicinal chemistry.

Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.

Andrew V. Anzalone, B. Ruggeri, T. Underiner, 2010, ACS medicinal chemistry letters.

new insights in ALK-mediated pathogenesis and the treatment of ALCL formyltransferase/IMP cyclohydrolase (ATIC) is enhanced by NPM-ALK: The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide

J. Nardone, O. Jensen, M. Comb, 2013 .

The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.

J. Nardone, J. Rush, G. Inghirami, 2009, Blood.

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

M. Wasik, B. Ruggeri, M. Marzec, 2008, Proceedings of the National Academy of Sciences.

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.

A. Ghose, K. L. Milkiewicz, T. Underiner, 2010, Bioorganic & medicinal chemistry.

Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Roberto Piva, Luca Agnelli, Antonino Neri, 2006, The Journal of clinical investigation.

Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.

B. Ruggeri, R. Haltiwanger, B. Dorsey, 2015, Bioorganic & medicinal chemistry letters.

Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of Zebrafish

R. Kelsh, M. Wasik, C. Winkler, 2013, PloS one.

PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas

S. Pileri, U. Jaeger, R. Eferl, 2012, Nature Medicine.

Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.

K. Wells-Knecht, H. Breslin, B. Dorsey, 2012, Journal of medicinal chemistry.

CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers

G. Inghirami, B. Ruggeri, D. Gingrich, 2011, Molecular Cancer Therapeutics.

Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.

Andrew V. Anzalone, Jason P. Burke, B. Ruggeri, 2011, Bioorganic & medicinal chemistry letters.

ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.

A. Ghose, B. Ruggeri, J. T. Durkin, 2009, Biochemistry.

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

Raffaella Faraoni, Darren E. Insko, P. Dobrzanski, 2012, Molecular Cancer Therapeutics.

Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology

J. O'neil, J. Cumming, A. Palani, 2021, ACS medicinal chemistry letters.

Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia.

C. Chiu, J. Metzger, Liming Yang, 2018, ACS medicinal chemistry letters.

Preclinical Development CEP-32496 : A Novel Orally Active BRAFV 600 E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

Raffaella Faraoni, Darren E. Insko, P. Dobrzanski, 2012 .

Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma

Patrick J. Curran, Chunsheng Zhang, An Chi, 2020, Cancer Immunology Research.

Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA

M. Wasik, Y. Yang, A. Woetmann, 2011, Oncogene.

Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors.

Patrick J. Curran, Theodore A. Martinot, Yongxin Han, 2021, ACS medicinal chemistry letters.

Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors.

T. Underiner, B. Dorsey, T. Angeles, 2011, Bioorganic & medicinal chemistry letters.

Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.

G. R. Ott, M. Cheng, 2010, Anti-cancer agents in medicinal chemistry.

Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates.

Ying Sun, P. Schultz, A. Palmieri, 2016, Journal of the American Chemical Society.

Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs.

Ying Sun, Rena Zhang, D. Bresson, 2016, Bioconjugate chemistry.

Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors.

Yongxin Han, N. Solban, X. Fradera, 2020, ACS medicinal chemistry letters.

2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formation.

M. Yazdanian, K. Wells-Knecht, D. Gingrich, 2011, Chemical research in toxicology.

The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1

G. Inghirami, E. Medico, L. Bonello, 2013, Oncogenesis.

J. Nardone, J. Rush, G. Inghirami, 2009, Blood.

Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.

R. Haltiwanger, B. Dorsey, T. Angeles, 2015, Bioorganic & medicinal chemistry letters.

A. Ghose, K. Wells-Knecht, H. Breslin, 2012, Journal of medicinal chemistry.

Opus: University of Bath Online Publication Store Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of Zebrafish

R. Kelsh, M. Wasik, C. Winkler, 2022 .